List of Genedata Biopharma Platform Customers
Basel, 4053,
Switzerland
Since 2010, our global team of researchers has been studying Genedata Biopharma Platform customers around the world, aggregating massive amounts of data points that form the basis of our forecast assumptions and perhaps the rise and fall of certain vendors and their products on a quarterly basis.
Each quarter our research team identifies companies that have purchased Genedata Biopharma Platform for Life Science R&D Platforms from public (Press Releases, Customer References, Testimonials, Case Studies and Success Stories) and proprietary sources, including the customer size, industry, location, implementation status, partner involvement, LOB Key Stakeholders and related IT decision-makers contact details.
Companies using Genedata Biopharma Platform for Life Science R&D Platforms include: Roche, a Switzerland based Life Sciences organisation with 112774 employees and revenues of $80.28 billion, AstraZeneca, a United Kingdom based Life Sciences organisation with 94300 employees and revenues of $73.98 billion, Merck, a United States based Life Sciences organisation with 73000 employees and revenues of $64.17 billion, Pfizer, a United States based Life Sciences organisation with 81000 employees and revenues of $63.63 billion, Bayer, a Germany based Life Sciences organisation with 92815 employees and revenues of $55.47 billion and many others.
Contact us if you need a completed and verified list of companies using Genedata Biopharma Platform, including the breakdown by industry (21 Verticals), Geography (Region, Country, State, City), Company Size (Revenue, Employees, Asset) and related IT Decision Makers, Key Stakeholders, business and technology executives responsible for the software purchases.
The Genedata Biopharma Platform customer wins are being incorporated in our Enterprise Applications Buyer Insight and Technographics Customer Database which has over 100 data fields that detail company usage of software systems and their digital transformation initiatives. Apps Run The World wants to become your No. 1 technographic data source!
Apply Filters For Customers
| Logo | Customer | Industry | Empl. | Revenue | Country | Vendor | Application | Category | When | SI | Insight |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Agenus | Life Sciences | 400 | $161M | United States | Genedata | Genedata Biopharma Platform | Life Science R&D Platforms | 2018 | n/a |
In 2018, Agenus implemented Genedata Biopharma Platform to consolidate antibody discovery workflows and support its immuno-oncology and vaccine R&D programs. The Genedata Biopharma Platform was deployed as an end-to-end Life Science R&D Platforms solution to standardize data capture and workflow management across research activities and to provide a single backbone for discovery-through-selection processes across the company.
The implementation configured modules for screening, engineering, expression, purification, and analytics for large-molecule and antibody workflows, including support for bispecifics and next-generation molecule types. Molecule, sample, assay, and analytics data flows were instrumented to capture developability and manufacturability attributes alongside experimental results, aligning platform capabilities with antibody discovery and candidate progression processes.
Genedata Biopharma Platform was integrated into Agenus’s broader data ecosystem, explicitly linking with the company’s Intelligent Re search AIR platform to enable shared access to large-molecule R&D data. Data and information were federated between project teams and research sites in the US and the UK, enabling cross-site collaboration and centralized access to assay and analytics outputs.
Governance and operational workflows were restructured to use the Genedata Biopharma Platform as the authoritative source for therapeutic candidate evaluation, enabling systematic and transparent decision-making when selecting candidates for clinical progression. The platform augmented Agenus scientists’ ability to capture, process, and interpret complex biologics data and served as a core component of the company’s collaborative data and information platform.
|
|
|
Amgen | Life Sciences | 28000 | $33.4B | United States | Genedata | Genedata Biopharma Platform | Life Science R&D Platforms | 2018 | n/a |
In 2018 Amgen implemented Genedata Biopharma Platform to support a new workflow for development of bispecific antibody therapeutics, targeting high-throughput binding and large molecule assay analysis. The deployment centered on discovery scientists analyzing high-volume assay outputs to accelerate candidate selection, and it is positioned within the Life Science R&D Platforms category to support research informatics needs.
The implementation relied on Genedata Screener as the analytic engine of the Genedata Biopharma Platform, applying automated analysis of high-volume data, automated fitting, and result derivation. Built-in business logic and pre-defined processing parameters were configured to standardize curve fitting, endpoint calculation, and result flagging, enabling repeatable, auditable processing of large molecule assay data.
Operational integration included reliable reporting pipelines to Amgen's data warehouse and generation of reports containing key result values and raw data traces for downstream review. Governance and process change emphasized consistent analysis through parameterized workflows and automated result derivation, and the initiative explicitly enabled rapid identification of rare bispecific molecules with promising properties, consistent analysis across experiments, and easier sharing of results via warehouse reporting.
|
|
|
AstraZeneca | Life Sciences | 94300 | $74.0B | United Kingdom | Genedata | Genedata Biopharma Platform | Life Science R&D Platforms | 2019 | n/a |
In 2019, AstraZeneca deployed the Genedata Biopharma Platform to automate mass spectrometry based high throughput screening data processing for Discovery Sciences in Cambridge, UK. The Genedata Biopharma Platform was implemented as a Life Science R&D Platforms solution to support Acoustic Mist Ionization Mass Spectrometry AMI MS workflows and centralize MS data handling for mechanistic biology and profiling teams.
Deployment centered on Genedata Expressionist as the primary processing module, configured with automated, customizable workflows that parse raw AMI MS files and assign spectra to individual wells from multi 384 well plate runs. Key capabilities implemented include dynamic peak detection and clustering algorithms, metadata driven automated processing, spectrum quality filtering, and configurable export pipelines, enabling single click processing of complex AMI MS data sets.
Integration workstreams routed processed results into the existing Genedata Screener analysis platform, with each AMI MS file automatically uploaded and processed using predefined workflows before seamless export to Screener for plate wise visualization and QC. The implementation explicitly supports AMI MS instrument output and high throughput screening pipelines, processing example data sets of 150 times 384 well plates within an automated end to end flow.
Governance was enforced through user definable settings and lockable workflows, enabling reproducible, auditable processing across laboratories and facilitating shared workflow templates for assay development. Detailed visualization and inspection at every processing stage were configured to support assay optimization, triage of false positives, and traceable data review practices.
Measured outcomes reported by AstraZeneca include a seven fold decrease in processing time with elimination of potentially error inducing manual interactions, with a representative workflow reducing processing from approximately three hours to around 25 minutes for large plate sets. The solution preserved flexibility to handle data from any mass spectrometer and to accommodate multiple assay strategies, while improving consistency and traceability of HTS MS data.
|
|
|
|
Life Sciences | 92815 | $55.5B | Germany | Genedata | Genedata Biopharma Platform | Life Science R&D Platforms | 2018 | n/a |
|
|
|
|
Life Sciences | 34100 | $48.3B | United States | Genedata | Genedata Biopharma Platform | Life Science R&D Platforms | 2022 | n/a |
|
|
|
|
Life Sciences | 60 | $15M | United Kingdom | Genedata | Genedata Biopharma Platform | Life Science R&D Platforms | 2018 | n/a |
|
|
|
|
Life Sciences | 6000 | $2.3B | Switzerland | Genedata | Genedata Biopharma Platform | Life Science R&D Platforms | 2020 | n/a |
|
|
|
|
Life Sciences | 2635 | $2.3B | Denmark | Genedata | Genedata Biopharma Platform | Life Science R&D Platforms | 2020 | n/a |
|
|
|
|
Life Sciences | 150 | $131M | United States | Genedata | Genedata Biopharma Platform | Life Science R&D Platforms | 2020 | n/a |
|
|
|
|
Life Sciences | 73000 | $64.2B | United States | Genedata | Genedata Biopharma Platform | Life Science R&D Platforms | 2019 | n/a |
|
Buyer Intent: Companies Evaluating Genedata Biopharma Platform
- Shimadzu, a Japan based Healthcare organization with 14219 Employees
- Irusri Sweden, a Sweden based Professional Services company with 10 Employees
- University at Buffalo, a United States based Education organization with 6037 Employees
Discover Software Buyers actively Evaluating Enterprise Applications
| Logo | Company | Industry | Employees | Revenue | Country | Evaluated | ||
|---|---|---|---|---|---|---|---|---|
| No data found | ||||||||